Skip to main content

A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Clinical Trial Grant
Duke Scholars

Awarded By

Argenx BV

Start Date

May 12, 2026

End Date

October 5, 2035
 

Awarded By

Argenx BV

Start Date

May 12, 2026

End Date

October 5, 2035